Bhandari Krishna Hari, Newa Madhuri, Yoon Sung Il, Kim Jung Sun, Kim Dae-Duk, Kim Jung Ae, Yoo Bong Kyo, Woo Jong-Soo, Lyoo Won Seok, Choi Jun Young, Lim Hyun Tae, Lee Jae H, Choi Han Gon, Yong Chul Soon
College of Pharmacy, Yeungnam University, 214-1, Dae-Dong, Gyongsan 712-749, South Korea.
J Pharm Pharm Sci. 2007;10(3):278-87.
Classic penetration enhancement/retardation methods for improved dermal drug delivery primarily focus on co-applied chemicals aided alterations in skin accumulation/permeation profile, and in many cases, this has been achieved by compromising the systemic absorption/toxicities of penetrant/enhancer/retarder. In this study, higher dermal accumulation without systemic absorption of ketorolac and its fatty esters (esters) will be achieved by synthesizing lipophilic fatty ester soft prodrugs of ketorolac.
Ketorolac decenoate (C10:1), dodecenoate (C12:1) and palmitoleate (C16:1) were synthesized and evaluated for their lipophilicity, enzymatic hydrolysis, chemical stabilities, and skin permeation and accumulation profiles using the combination of common permeation enhancing techniques such as the use of lipophilic receptor solution, enhancer pretreatment of skins, removal of stratum corneum and delipidization of skins etc.
Esters were highly lipophilic, chemically stable, enzymatically unstable in hairless mouse skin/liver homogenates and impermeable into the receptor solution.
Higher dermal accumulation, absence of skin permeation, relative enzymatic stability in whole skins during permeation study and the pharmaceutical stability of esters could delineate a preliminary possibility for designing safer dermal agents with minimum potential for systemic absorption without the co-application of permeation enhancers or retarders.
经典的用于改善皮肤药物递送的渗透增强/延缓方法主要集中在共同应用化学物质以辅助改变皮肤蓄积/渗透情况,并且在许多情况下,这是通过牺牲渗透剂/增强剂/阻滞剂的全身吸收/毒性来实现的。在本研究中,通过合成酮咯酸的亲脂性脂肪酸酯前药,将实现酮咯酸及其脂肪酸酯在无全身吸收情况下的更高皮肤蓄积。
合成了酮咯酸癸烯酸酯(C10:1)、十二碳烯酸酯(C12:1)和棕榈油酸酯(C16:1),并使用常见的渗透增强技术组合,如使用亲脂性受体溶液、对皮肤进行增强剂预处理、去除角质层和使皮肤脱脂等,对它们的亲脂性、酶促水解、化学稳定性以及皮肤渗透和蓄积情况进行评估。
酯类具有高度亲脂性、化学稳定,在无毛小鼠皮肤/肝脏匀浆中酶促不稳定且不能渗透到受体溶液中。
更高的皮肤蓄积、无皮肤渗透、在渗透研究期间在整个皮肤中的相对酶稳定性以及酯类的药物稳定性,可以勾勒出一种初步可能性,即无需共同应用渗透增强剂或阻滞剂就能设计出全身吸收潜力最小的更安全皮肤制剂。